DDS Wireless Launches Scheduled Routes: A Powerful Routing & Scheduling Optimization Solution
6.3.2025 19:17:00 CET | Business Wire | Press Release
DDS Wireless, a global leader in fleet management technology, has officially launched Scheduled Routes, an advanced Routing & Scheduling Optimization solution designed to help businesses improve fleet efficiency, reduce costs, and enhance service reliability. With the ability to process up to 50,000 stops per call—ten times the industry standard—Scheduled Routes delivers a next-generation approach to fleet optimization. Leveraging cutting-edge algorithms, the solution dynamically adjusts routes based on capacity, time windows, vehicle availability, and real-time traffic conditions. This results in greater efficiency, reduced costs, and improved service reliability at scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250305795793/en/
"Scheduled Routes is ready to help businesses transform their operations today," said Jason Piippo, VP of Sales at DDS Wireless. "Our solution delivers immediate value by cutting costs, increasing efficiency, and ensuring fleets operate at peak performance."
Designed to increase fleet efficiency by up to 20%, reduce total fleet mileage by up to 30%, and achieve 95%+ on-time performance, Scheduled Routes also helps businesses streamline operations by reducing route planning time by up to 80%. The platform includes a Custom Strategy Maker, allowing companies to define optimization objectives tailored to their specific needs, and seamlessly integrates with enterprise systems such as ERP, CRM, and fleet management tools. Flexible access via API, SDK, or a client app ensures seamless deployment across different operational environments.
Built for diverse applications, Scheduled Routes supports logistics, last-mile delivery, field service management, on-demand delivery services, waste collection, and passenger transportation. With rising fuel costs, increasing customer demands, and evolving regulatory pressures, businesses require scalable, intelligent routing solutions. Scheduled Routes optimizes fleet movements, minimizes unnecessary mileage, and enhances on-time performance, ensuring maximum asset utilization while reducing emissions and operational waste.
With increasing operational challenges, businesses can’t afford inefficiencies. Scheduled Routes is the intelligent, scalable solution they need to stay competitive. Learn more and optimize your fleet today at www.ddswireless.com/scheduled-routes.
About DDS Wireless International
For over three decades, DDS Wireless has been at the forefront of fleet management innovation, pioneering GPS dispatching, mobile integration, and intelligent routing. Headquartered in Vancouver, BC, Canada, DDS Wireless operates globally through subsidiaries including StrataGen Systems in North America and MobiSoft Oy in Europe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250305795793/en/
Contacts
For media inquiries, please contact:
Cesar Bohorquez
Head of Marketing
DDS Wireless International
p: 604-401-0767
e: cbohorquez@ddswireless.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom